

Drug Safety Oversight Board Roster

Chair (Non-voting)

- Paul Seligman, M.D.,M.P.H.
Associate Director for Safety Policy and Communication
Center for Drug Evaluation and Research

Executive Secretary (Non-voting)

- Steven Osborne, M.D.
Executive Director, Drug Safety Oversight Board
Safety Policy and Communication

Office of Medical Policy, Center for Drug Evaluation and Research

Primary Member:

- Robert Temple, M.D., Director, Office of Medical Policy

Alternate Member:

- Rachel Behrman, M.D., Deputy Director, Office of Medical Policy

Office of New Drugs, Center for Drug Evaluation and Research

Primary Members:

- John Jenkins, M.D., Director, Office of New Drugs
- Debra B. Birnkrant, M.D., Director, Division of Antiviral Products
- Daniel Shames, M.D., Deputy Director, Office of Drug Evaluation III

Alternate Members:

- Sandra Kweder, M.D., Deputy Director, Office of New Drugs
- Charles J. Ganley, M.D., Director, Office of Nonprescription Products
- Bob A. Rappaport, M.D., Director of Anesthesia, Analgesic and Rheumatology Products

Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research

Primary Members:

- Gerald Dal Pan, M.D., Director, Office of Surveillance and Epidemiology
- Mark I. Avigan, M.D., Director, Division of Drug Risk Evaluation
- Solomon Iyasu, M.D., M.P.H., Director, Division of Surveillance and Communication Support

Alternate Members:

- Henry « Skip » Francis, M.D., Deputy Director, Office of Surveillance and Epidemiology
- Carol A. Holquist, R. Ph., Director, Division of Medical Errors and Technical Support
- Toni Piazza-Hepp, Pharm. D., Deputy Director, Division of Surveillance and Communication Support
- Ann McMahan, M.D., M.S., Deputy Director, Division of Drug Risk Evaluation
- Judy Staffa, Ph.D., R.Ph., Acting Associate Director for Regulatory Research

- **Office of Translational Sciences, Center for Drug Evaluation and Research**

Immediate Office

Primary Member:

- ShaAvhree Buckman, M.D., Deputy Director, Office of Translational Sciences

Alternate Member:

- Robert Powell, Dr.Ph., Senior Pharmacist, Office of Translational Sciences

Office of Biostatistics

Primary Member:

- Robert O'Neill, Ph.D., Director, Office of Biostatistics

Alternate Member:

- Aloka Chakravarty, Ph. D., Director, Biologic Therapeutics Statistical Staff

Office of Clinical Pharmacology

Primary Member:

- Lawrence Lesko, Ph.D., Director, Office of Clinical Pharmacology

Alternate Member:

- Shiew-Mei Huang, Ph.D.,FCP, Deputy Director, Office of Clinical Pharmacology

Office of Counterterrorism and Emergency Coordination, Center for Drug Evaluation and Research

Primary Member:

- Rosemary Roberts, M.D., Director, Office of Counterterrorism and Emergency Coordination

Alternate Member:

- Susan McCune, M.D., Associate Director of Emergency Risk Communication

Office of Compliance, Center for Drug Evaluation and Research

Primary Member:

- Jason J.Y. Woo, M.D., M.P.H., Associate Director for Scientific and Medical Affairs, Office of Compliance

Alternate Member:

- Joseph Famulare, Deputy Director, Office of Compliance

Office of Pharmaceutical Science, Center for Drug Evaluation and Research

Primary Member:

- Nancy Chang, M.D., Office of Generic Drugs

Alternate Member:

- Lawrence Yu, Ph.D., Director for Science, Office of Generic Drugs
- Dena Hixon, M.D., Associate Director of Medical Affairs, Office of Generic Drugs

Center for Biologic Evaluation and Research, Food and Drug Administration

Primary Member:

- Miles Braun, M.D., Director, Division of Epidemiology, Center for Biologic Evaluation and Research

Alternate Member:

- Robert Ball, M.D., Chief of Vaccine and Safety Branch, Office of Biostatistics and Division of Epidemiology, Division of Epidemiology, Center for Biologic Evaluation and Research

Center for Devices and Radiological Health, Food and Drug Administration

Primary Member:

- Kimber Richter, M.D., Deputy Director for Medical Affairs, Office of Compliance

Alternate Member:

- Thomas P. Gross, M.D., M.P.H, Division of Postmarket Surveillance

Department of Veterans Affairs

Primary Member:

- C. Bernie Good, M.D., M.P.H., Chairman, Medical Advisory Panel for Pharmacy Benefits Management, Veterans Administration Pittsburgh Health Care System

Alternate Member:

- Peter Glassman, M.D., Staff Physician, Veterans Administration Hospital of Greater Los Angeles , Co-Director, Center for Medication Safety , Veterans Administration

National Institutes of Health, National Cancer Institute

Primary Member:

- Anthony J. Murgo, M.D., M.S., Head, Early Clinical Trials Development, Division of Cancer Treatment and Diagnosis

Alternate Member:

- Margaret Mooney, M.D., Clinical Investigations Branch, Cancer Treatment Evaluation Program

National Institute of Health, Office of Biotechnology Activities

Primary Member:

- Amy P. Patterson, M.D., Director, Clinical Research Policy Analysis and Coordination Program

Center for Disease Control

Primary Member:

- Dan Budnitz, M.D., MPH, CDR, USPHS, Division of Healthcare Quality Promotion

Alternate Member:

- Daniel Pollock, M.D., Division of Healthcare Quality Promotion

Agency for Healthcare Research and Quality

Primary Member:

- Anne E. Trontell, M.D., M.P.H., Sr. Advisor on Pharmaceutical Outcomes and Risk Management

Alternate Member:

- Scott R. Smith, Ph.D., Director, Pharmaceutical Outcomes Research, Center for Outcomes and Evidence